Raymond James Financial
PRQR icon

Raymond James Financial’s ProQR Therapeutics PRQR Stock Holding History

Raymond James Financial’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
571,073
+24,994
+5% +$41.2K ﹤0.01% 3955
2026
Q1 		$885K Buy
546,079
+203,193
+59% +$333K ﹤0.01% 3947
2025
Q4 		$693K Buy
342,886
+232,616
+211% +$544K ﹤0.01% 4032
2025
Q3 		$235K Buy
110,270
+14,549
+15% +$31.8K ﹤0.01% 4535
2025
Q2 		$195K Sell
95,721
-6,395
-6% -$10.4K ﹤0.01% 4529
2025
Q1 		$136K Buy
102,116
+4,188
+4% +$8.91K ﹤0.01% 4495
2024
Q4 		$260K Buy
+97,928
New +$311K ﹤0.01% 4265

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Raymond James Financial's PRQR Position: Q2 2026 in Review

Raymond James Financial increased its ProQR Therapeutics (PRQR) stake by 4.6% in Q2 2026, buying an estimated $41.2K and bringing the position to 571,073 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3955.

Raymond James Financial first reported a position in PRQR in Q4 2024 and has held it in 7 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Raymond James Financial held 571,073 shares of ProQR Therapeutics worth $1.06M as of Q2 2026.
  • Raymond James Financial bought 24,994 ProQR Therapeutics shares in Q2 2026, an estimated $41.2K.
  • ProQR Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3955 holding.
  • Raymond James Financial first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.